Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

Major Program

Phase 0 I II Cancer Prevention Clinical Trials Program

Research Group

Gastrointestinal and Other Cancers

Status

Completed

NCT ID

NCT02365480

This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce the risk of colorectal cancer. Patients with ulcerative colitis are at increased risk for colorectal cancer. Chemoprevention is the use of drugs, such as berberine chloride, to keep a disease/condition from forming or coming back. The use of berberine chloride may keep colorectal cancer from forming in patients with ulcerative colitis.

Intervention

Berberine Chloride, Laboratory Biomarker Analysis, Placebo Administration

Condition

Ulcerative Colitis

Investigators

Kaichun Wu

See list of participating sites